Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bladder Cancer AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Bladder Cancer AND Cancer. Displaying page 11 of 19.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2019-000572-41 Sponsor Protocol Number: LUC19-002 Start Date*: 2019-04-29
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced « cold » solid tumors
    Medical condition: Indication of treatment with anti-PD1 antibodies such as • Melanoma non BRAF mutated in first line of treatment • Melanoma BRAF mutated in first or second line of treatment • Lung cancer (NSCLC) in...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002577-33 Sponsor Protocol Number: ICR-CTSU/2011/10031 Start Date*: 2012-01-04
    Sponsor Name:Institute of Cancer Research
    Full Title: A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer
    Medical condition: Upper urinary tract transitional cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044407 Transitional cell cancer of the renal pelvis and ureter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001920-36 Sponsor Protocol Number: NIMAO/2018-01/JF-01 Start Date*: 2020-12-03
    Sponsor Name:CHU de NIMES
    Full Title: Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence befo...
    Medical condition: patients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003636-79 Sponsor Protocol Number: 18-214-10/CA045-012 Start Date*: 2019-09-02
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients
    Medical condition: Locally advanced or metastatic urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) NL (Completed) DK (Completed) FI (Completed) DE (Completed) PL (Completed) GR (Completed) BE (Completed) AT (Completed) ES (Prematurely Ended) FR (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007943-29 Sponsor Protocol Number: EFC6521 Start Date*: 2008-07-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk ...
    Medical condition: The subjects who will participate to this clinical trial are cancer patients (i.e. patients with metastatic or locally advanced tumor of the lung, pancreas, stomach, colon/ rectum, bladder or ovary...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) AT (Completed) LV (Completed) EE (Completed) SE (Completed) SK (Completed) NL (Completed) PT (Completed) LT (Completed) BE (Completed) DK (Completed) CZ (Completed) FI (Completed) SI (Completed) IT (Completed) BG (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002758-35 Sponsor Protocol Number: IJB-AURA-ODN-004 Start Date*: 2018-05-16
    Sponsor Name:Insitut Jules Bordet
    Full Title: Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers
    Medical condition: Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003809-26 Sponsor Protocol Number: MK-3475-905 Start Date*: 2019-07-01
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who ...
    Medical condition: Muscle-invasive Bladder Cancer (MIBC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002628-18 Sponsor Protocol Number: HIVECI Start Date*: 2013-12-16
    Sponsor Name:COMBAT MEDICAL LTD
    Full Title: HIVEC (Hyperthermic IntraVEsical Chemotherapy) FOR PATIENTS WITH INTERMEDIATE RISK NMIBC COMPARED WITH STANDARD INTRAVESICAL INSTILLATION OF CHEMOTHERAPY AS ADYUVANT TREATMENT. A COMPARATIVE, PROS...
    Medical condition: NON MUSCULAR INVASIVE BLADDER CANCER WITH INTERMEDIATE RISK OF RECURRENCE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002534-37 Sponsor Protocol Number: RAME-04 Start Date*: 2021-03-08
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy
    Medical condition: bladder cancer patients eligible for cisplatin chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006214-26 Sponsor Protocol Number: GU07-123 Start Date*: 2009-09-07
    Sponsor Name:Hoosier Oncology Group
    Full Title: Phase II Trial of Neoadjuvent Cisplatin, Gemcitabine and Sunitinib Malate followed by radical cystectomy for transitional Cell Carcinoma (TCC) of the bladder
    Medical condition: operable bladder cancer (T2 to T4a) lymph node negative disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005403-17 Sponsor Protocol Number: KH-MS-JAW-01 Start Date*: 2007-12-10
    Sponsor Name:GE Healthcare
    Full Title: A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma
    Medical condition: Upper urinary tract (ureters and pyela/renal pelvises) urothelial cell carcinoma for which blue light uretero-renoscopy and biopsies are performed for diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026431 Malignant neoplasm of renal pelvis and ureter transitional cell regional LLT
    9.1 10038497 Renal pelvis and ureter transitional cell cancer localized LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001688-22 Sponsor Protocol Number: 01CCRe-IV Start Date*: 2013-08-23
    Sponsor Name:Servicio de Cirugía General y Digestiva Hospital Universitario de Bellvitge
    Full Title: Randomized multicenter trial in colorectal cancer patients with non-resectable metastasis. Impact of tumor resection versus chemotherapy alone in survival.
    Medical condition: Cancer colorectal stage IV with synchronous non-resectable metastasis.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000043-32 Sponsor Protocol Number: NA Start Date*: 2014-03-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract
    Medical condition: Non-transitional cell carcinoma of the bladder and the urinary tract
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001074-15 Sponsor Protocol Number: GEN701 Start Date*: 2013-10-08
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, dose-escalating safety study of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors kno...
    Medical condition: Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (n...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014742 Endometrial neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001633-24 Sponsor Protocol Number: D419BC00001 Start Date*: 2015-11-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in ...
    Medical condition: Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothe...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10022880 Invasive bladder cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) DK (Completed) ES (Ongoing) GR (Trial now transitioned) PT (Completed) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002625-11 Sponsor Protocol Number: MO29983 Start Date*: 2016-12-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT
    Medical condition: Advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) EE (Completed) LT (Completed) DE (Completed) HU (Completed) IE (Completed) DK (Completed) CZ (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BG (Completed) NL (Completed) PL (Completed) ES (Completed) BE (Completed) SK (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002934-32 Sponsor Protocol Number: D4884C00001 Start Date*: 2015-12-15
    Sponsor Name:AstraZenenca AB
    Full Title: A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
    Medical condition: Adult patients (age ≥18 years) with advanced and metastatic solid tumors including but not limited to histologically or cytologically documented UBC, PDAC, or TNBC.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071664 Bladder transitional cell carcinoma metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000272-34 Sponsor Protocol Number: L00070-IN-214-P1 Start Date*: 2011-08-29
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the...
    Medical condition: Advanced or metastatic predominantly transitional cell carcinoma of the urothelial tract.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003699-13 Sponsor Protocol Number: MAK-BLA-202 Start Date*: 2005-03-08
    Sponsor Name:INMUNO DESIGNED MOLECULES (IDM)
    Full Title: Phase II/III, Multicenter, Open-label, Randomized Study Comparing Autologous Intravesical Macrophage Cell Therapy (“Bexidem”) to Intravesical BCG-Therapy in Patients With Superficial Papillary Blad...
    Medical condition: BLADDER CANCER AFTER TRANSURETRHAL RESECTION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 15:43:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA